live attenuated tetravalent dengue vaccine (KD-382) / Meiji Seika - LARVOL DELTA

Cross-genotype immunogenicity and antibody-dependent enhancement of KD-382 dengue vaccine in flavivirus-naïve adults. (PubMed, NPJ Vaccines) - "Using single-round infectious particles representing 17 dengue virus genotypes, KD-382-induced antibodies demonstrated durable cross-genotype neutralizing activity, with minimal in vitro ADE risk. These findings highlight KD-382's potential for broad protection and underscore the importance of long-term monitoring in dengue-naïve populations."

Journal • Dengue Fever

A phase I, randomized, placebo-controlled, double-blind, ascending-dose and single-center study to evaluate immunogenicity and safety of a live attenuated tetravalent dengue vaccine (KD-382) in Flavivirus antibody-naïve healthy adults. (PubMed, Vaccine) - P1 | "KD-382 was safe and well-tolerated in flavivirus antibody-naïve healthy subjects. It elicited a long-lasting neutralizing antibody response for all four DENV serotypes during the 1-year follow-up, even with single-dose administration. Australia New Zealand Clinical Trial Registry: ACTRN12618001027202."

Journal • Dengue Fever • Dermatology • Fatigue • Hematological Disorders • Musculoskeletal Pain • Pain • Pruritus